{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"41"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"133"}],"units":"Participants"}],"groups":[{"description":"Participants received cemiplimab 3 milligrams (mg)/kilogram (kg) intravenously (IV) every 2 weeks (Q2W) during each 8-week treatment cycle, for up to 96 weeks (12 cycles).","id":"OG000","title":"Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W"},{"description":"Participants received cemiplimab 3 mg/kg IV Q2W during each 8-week treatment cycle, for up to 96 weeks (12 cycles).","id":"OG001","title":"Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W"},{"description":"Participants received cemiplimab 350 mg IV every 3 weeks (Q3W) during each 9-week treatment cycle, for up to 54 weeks (6 cycles).","id":"OG002","title":"Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W"},{"description":"Participants received cemiplimab 600 mg IV every 4 weeks (Q4W) during each 8-week treatment cycle, for up to 48 weeks (6 cycles).","id":"OG003","title":"Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W"},{"description":"Participants received a single 438 mg subcutaneous (SC) dose of cemiplimab followed by cemiplimab 350 mg IV Q3W during each 9-week treatment cycle, for up to 54 weeks (6 cycles).","id":"OG004","title":"Group 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3W"},{"description":"Participants received cemiplimab 350 mg IV Q3W during each 9-week treatment cycle, for up to 108 weeks (12 cycles).","id":"OG005","title":"Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Anti-drug Antibody (ADA) population for cemiplimab included all treated participants who had at least 1 postdose ADA result for cemiplimab.","reportingStatus":"POSTED","timeFrame":"Up to approximately 43 months","title":"Number of Participants With Treatment-Emergent Anti-cemiplimab Antibodies","type":"SECONDARY","unitOfMeasure":"Participants"}